Precigen, Inc.
(NASDAQ : PGEN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. 1.46%243.821.3%$795.90m
IMMUImmunomedics, Inc. 0.07%85.3611.0%$697.18m
MRNAModerna, Inc. 6.60%69.470.0%$666.49m
NVAXNovavax, Inc. 10.86%113.5696.5%$629.01m
ILMNIllumina, Inc. 4.74%299.893.5%$582.79m
GILDGilead Sciences, Inc. 0.00%62.251.0%$574.11m
REGNRegeneron Pharmaceuticals, Inc. 2.98%574.062.7%$443.39m
VRTXVertex Pharmaceuticals, Inc. 1.92%268.181.9%$340.86m
BIIBBiogen, Inc. 1.20%273.281.6%$334.97m
ALXNAlexion Pharmaceuticals, Inc. 2.15%114.432.0%$285.22m
EXASEXACT Sciences Corp. 3.60%97.7020.7%$257.29m
SRNESorrento Therapeutics, Inc. 4.84%9.641.5%$240.99m
VXRTVaxart, Inc. 7.40%7.400.0%$213.88m
SGENSeattle Genetics, Inc. 3.08%184.956.0%$212.14m
MNTAMomenta Pharmaceuticals, Inc. 0.02%52.403.0%$193.58m

Company Profile

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, MBP Titan, Trans Ova and All Other. The PGEN Therapeutics segment is advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The ActoBio segment involves in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The MBP Titan segment comprises of Methane Bioconversion Platform, and associated technologies, personnel, and facilities The Trans Ova segment includes provides advanced reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.